Easier Alzheimer's Care, a Gum-Heart Warning, and Unexpected Lung Cancer Findings

Two major medical conferences convened this weekend — the Alzheimer's Association International Conference (AAIC 2026) in London and the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions in Boston — delivering a concentrated set of clinical findings across neurology, cardiology, and dermatology. The results include a meaningful quality-of-life advance for Alzheimer's patients, a global dementia-risk atlas, a gum-disease–heart-valve connection, a lung-cancer signal in young non-smokers, and a Phase 2a milestone for an alopecia drug.

Monday, 13 July: Leqembi Gets a Monthly Subcutaneous Form — an Alzheimer's Access Milestone

Eisai and Biogen presented data at AAIC 2026 in London showing that a once-monthly subcutaneous autoinjector formulation of lecanemab (brand name: Leqembi) delivers efficacy and safety comparable to the currently approved biweekly intravenous infusion in people with early Alzheimer's disease.

Leqembi is an anti-amyloid monoclonal antibody approved by the FDA in 2023 and by the EMA in 2024. Its current form requires patients to travel to an infusion centre every two weeks — a significant burden for older adults with cognitive impairment and their carers. A monthly self-injectable form would bring treatment far closer to home. Data from the Phase 3 autoinjector study showed comparable CDR-SB progression scores and amyloid-clearing PET results between IV and SC cohorts, with rates of amyloid-related imaging abnormalities (ARIA) — the key safety concern — not significantly higher in the subcutaneous group. Eisai expects to submit a supplemental regulatory application later in 2026. A subcutaneous route would also lower delivery costs, potentially widening access in countries with limited infusion infrastructure, including many in the eastern Mediterranean.

Monday, 13 July: A Global Atlas Finds Dementia Risk Tied to Where You Live

A large epidemiological study presented at AAIC on Monday mapped dementia risk factors across dozens of countries and found they differ markedly by setting. In high-income countries, cardiovascular factors — hypertension, obesity, and physical inactivity — dominate. In lower- and middle-income settings, limited formal education, air pollution, and uncorrected hearing loss carry far greater relative weight.

The finding has direct policy implications: a dementia-prevention programme effective in Northern Europe may need significant redesign for communities in the eastern Mediterranean, where the higher-leverage interventions are access to education and hearing care, not primarily diet or weight management. The study is consistent with the 2024 Lancet Commission on dementia prevention, which identified 14 modifiable risk factors accounting for approximately 45% of dementia cases globally. For older adults in Cyprus and neighbouring countries, the protective value of sustained social engagement — which untreated hearing loss progressively erodes — deserves wider public-health emphasis.

Monday, 13 July: Pepinemab Targets Neuroinflammation in Alzheimer's — A New Pathway at AAIC

Also at AAIC, Vaccinex reported Phase 1b/2 biomarker results from the SIGNAL-AD trial of pepinemab, a monoclonal antibody that blocks Semaphorin-4D (SEMA4D), a signalling protein involved in activating inflammatory glial cells in the brain. Unlike lecanemab and donanemab, which target amyloid plaques, pepinemab works upstream of neuroinflammation — aiming to prevent the reactive astrocyte and microglial cascades that accelerate neurodegeneration.

The SIGNAL-AD results showed that pepinemab shifted glial biomarker profiles in people with early Alzheimer's disease in ways consistent with reduced neuroinflammation. Vaccinex plans to launch an expanded Phase 2b trial (SIGNAL-AD2) later in 2026. These are early-stage biomarker data — not yet efficacy evidence from a definitive clinical outcome trial — and the mechanism remains unvalidated at the clinical level. But a neuroinflammatory approach is mechanistically complementary to amyloid-clearing strategies, representing a genuinely distinct avenue in a disease that has resisted drug development for decades.

Sunday–Monday, 12–13 July: Gum Bacteria May Be Hardening the Aortic Valve

Preliminary research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions in Boston identified Porphyromonas gingivalis — the bacterium most responsible for chronic periodontal (gum) disease — as a potential driver of calcific aortic valve stenosis (CAVS), the most common heart valve disease in older adults.

CAVS occurs when the aortic valve thickens and accumulates calcium deposits, restricting blood flow from the heart to the body. In early stages there may be no symptoms; as it progresses, it causes fatigue, chest pain, shortness of breath, and fainting, with eventual risk of heart failure. The only treatment is valve replacement. The new research proposes a biological pathway: P. gingivalis entering the bloodstream through inflamed gum tissue may trigger inflammatory signalling in valve-endothelial cells and promote pathological calcium deposition. These findings are from a conference abstract, not yet a peer-reviewed publication, and investigators describe them as preliminary. If confirmed in larger studies, CAVS would join endocarditis, stroke, and coronary artery disease on the list of systemic conditions associated with chronic periodontal infection.

Even before a causal link is established, the practical message carries weight: adults with active gum disease carry elevated systemic inflammatory burden. Treating periodontal disease is low-cost and low-risk. For Mediterranean communities, where periodontal disease is prevalent among adults over 60 and CAVS is widespread, regular dental check-ups represent a high-value public health investment.

Saturday, 12 July: A Pesticide Hypothesis for Lung Cancer in Healthy Young Non-Smokers

Researchers at the USC Norris Comprehensive Cancer Center, presenting at the American Association for Cancer Research meeting, reported a counterintuitive finding: among 187 young lung cancer patients who had never smoked, diet quality was higher than the US national average, with participants consuming more dark green vegetables, legumes, and whole grains — foods conventionally associated with cancer protection.

The team's hypothesis is that conventionally grown fruits, vegetables, and whole grains carry higher pesticide residues than many animal products or processed foods, and cumulative pesticide exposure from a health-conscious but non-organic diet may contribute to lung carcinogenesis in genetically susceptible people. Women under 50 who have never smoked already develop early-onset lung cancer at higher rates than comparable men, a pattern that remains poorly understood. The study is small (187 patients), observational, and not yet peer-reviewed. The investigators explicitly caution against reducing fruit and vegetable intake — the overall evidence for plant-rich diets protecting against cancer remains strong across the population. The signal, if replicated, would point toward organic produce for high-risk individuals, not toward abandoning vegetables. Larger prospective studies comparing organic and conventional produce intake are now being called for.

Monday, 13 July: Bempikibart Clears Phase 2a Bar for Severe Alopecia Areata

Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart (ADX-914), an antibody that blocks the shared receptor for interleukins IL-7 and IL-21 — two cytokines involved in the autoimmune attack on hair follicles that characterises alopecia areata.

In the modified intent-to-treat population, 40% of participants achieved a SALT-20 response (at least a 20-point improvement in the Scalp Hair Loss Assessment Tool score) at 36 weeks. The therapy was well tolerated, with no treatment-related serious adverse events or grade ≥3 adverse events reported. Q32 Bio intends to advance bempikibart into a Phase 3 registration-directed programme in the first half of 2027. Alopecia areata affects roughly 2% of the global population and causes significant psychological distress. Existing treatments — particularly JAK inhibitors baricitinib and ritlecitinib — carry immunosuppressive risk profiles. Bempikibart's distinct IL-7/IL-21 pathway may offer a different tolerability profile; Phase 3 data, expected in 2028–2029, will be the definitive test.

The content of this article is journalistic and is intended for informational purposes only. It does not constitute medical advice. Please consult a qualified clinician before making any change to your treatment, medication, or health decisions.